Kurt Gish, Ph.D.
CEO & Co-Founder at Trilo Therapeutics
Kurt Gish has extensive experience in the pharmaceutical and biotechnology industry. Kurt is currently serving as the CEO and Co-Founder of Trilo Therapeutics, a position they have held since 2021. Prior to this, they co-founded the company and served as the Chief Scientific Officer.
Before their time at Trilo Therapeutics, Gish worked at various organizations in leadership roles. Kurt spent five years at AbbVie as the Associate Director II of Discovery, leading the ADC Discovery group in developing antibody-drug conjugates for oncology. Prior to AbbVie, Gish worked at Abbott Biotherapeutics Corp. as an Associate Director of Discovery, managing a team and focusing on the development of ADCs for oncology.
Gish also held the position of Director of Research at Facet Biotech, where they managed a team and worked on the development of monoclonal antibody therapeutics for oncology. Kurt served as Director of Research at PDL BioPharma, managing a larger team and focusing on the development of monoclonal antibody therapeutics for oncology and autoimmune disease.
Before their leadership roles, Gish worked as a Senior Scientist at Eos Biotechnology, conducting genome-wide gene regulation studies for cancer-specific molecules. Kurt also worked at Affymetrix as a Scientist, focusing on gene regulation studies for cancer-specific genes. Gish began their career as a Postdoctoral Fellow at DNAX Research Institute, where they conducted novel gene discovery and gene regulation studies.
Throughout their career, Gish has accumulated expertise in the development of first-in-class antibody-drug conjugates and monoclonal antibody therapeutics for oncology.
Kurt Gish has a strong educational background in the field of biology. Kurt received their Bachelor of Science degree in Biology from UC Irvine in 1987. Kurt then went on to pursue further education and obtained their Ph.D. in Biology from Stanford University in 1994. Following their doctoral studies, Kurt Gish joined the DNAX Research Institute for a Post-Doctoral Fellowship in Molecular Immunology, where they engaged in research and scholarly activities from 1994 to 1997.